Gland Pharma Limited has informed the Exchange regarding a press release dated April 03, 2025, titled "Gland Pharma receives approval for Acetaminophen Injection".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma Limited has announced that it has received approval for Acetaminophen Injection, as disclosed via a press release dated April 03, 2025. Acetaminophen is the generic name for paracetamol, a widely used pain and fever reducer. The approval is likely from the USFDA, consistent with Gland Pharma's focus on injectable generics for the US market. This adds another product to the company's injectable portfolio, strengthening its presence in the hospital and acute care segment. No specific financial impact or revenue guidance was provided in the announcement.
This approval expands Gland Pharma's product basket and could contribute to incremental revenues from the US market in the coming quarters. Short-term stock reaction may be muted unless the product carries significant commercial value, but it adds to the company's pipeline strength.